SBTX vs. ONC, OBD, DEST, OPTI, HEMO, OBI, NSCI, C4XD, SNG, and SAR
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include Oncimmune (ONC), Oxford BioDynamics (OBD), Destiny Pharma (DEST), OptiBiotix Health (OPTI), Hemogenyx Pharmaceuticals (HEMO), Ondine Biomedical (OBI), NetScientific (NSCI), C4X Discovery (C4XD), Synairgen (SNG), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
Oncimmune (LON:ONC) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability.
Oncimmune has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
In the previous week, SkinBioTherapeutics' average media sentiment score of 0.61 beat Oncimmune's score of 0.00 indicating that Oncimmune is being referred to more favorably in the media.
Oncimmune received 21 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. However, 60.26% of users gave SkinBioTherapeutics an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
35.5% of Oncimmune shares are held by institutional investors. Comparatively, 12.0% of SkinBioTherapeutics shares are held by institutional investors. 28.8% of Oncimmune shares are held by company insiders. Comparatively, 28.1% of SkinBioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Oncimmune has a net margin of 356.25% compared to Oncimmune's net margin of 0.00%. Oncimmune's return on equity of -118.63% beat SkinBioTherapeutics' return on equity.
SkinBioTherapeutics has lower revenue, but higher earnings than Oncimmune. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
Summary
Oncimmune beats SkinBioTherapeutics on 8 of the 14 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
